Pharmaceutical R&D · near ·
The biologics discovery mechanism is creating an unmet need
The pharmaceutical industry is experiencing an acceleration in R&D driven by specialised AI models that deliver unprecedented performance gains, such as 100x improvement in biologics discovery hit rates and 10x in target identification. This shift towards highly specialised AI is fundamentally changing drug pipeline development.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.